MicroRNA-506 is up-regulated in the development of pancreatic ductal adenocarcinoma and is associated with attenuated disease progression
© The Author(s) 2016
Received: 14 March 2016
Accepted: 22 June 2016
Published: 2 July 2016
MicroRNA-506 (miR-506) has been reported to function in several tumors as a tumor suppressor gene or oncogene. However, the expression and role of miR-506 in pancreatic ductal adenocarcinoma (PDAC) remains unclear. In this study, we aimed to evaluate the phenotype of miR-506 in PDAC.
Using miRNA in situ hybridization, we examined the expression of miR-506 in 113 PDACs and 87 paired normal pancreatic tissues. We evaluated miR-506 expression in PDAC cells, normal pancreatic ducts, and acinus/islands, and we analyzed the associations between miR-506 expression and the clinicopathologic characteristics of PDAC patients.
miR-506 expression was higher in PDAC than in matched normal pancreatic ductal cells (P < 0.001). On the other hand, the combined group of well and moderately differentiated PDACs showed higher levels of miR-506 than the poorly differentiated ones (P = 0.023). Moreover, miR-506 expression was negatively associated with pathologic T category (P = 0.004) and lymph node metastasis (P = 0.033), suggesting that miR-506 might inhibit the progression of PDAC.
Our results suggest that miR-506 either plays a role as an oncogene in the tumorigenesis and a tumor suppressor in the progression or serves as a house-keeping, tumor-suppressing miRNA, whose expression can be activated by oncogenic signals in early development to hinder the progression of PDAC.
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy, with a median patient survival of 6 months and a 5-year overall survival rate of 5% [1, 2]. The high rate of lethality from PDAC is primarily due to the advanced stage of disease at diagnosis, which precludes curative surgery and leads to a poor prognosis. Therefore, to improve patient survival, early diagnosis of PDAC is extremely important. Routine imaging methods, such as ultrasound, computed tomography, and magnetic resonance imaging, are not sensitive enough in early detection of PDAC . Although carbohydrate antigen 19-9 (CA19-9) is considered the most useful biomarker in the early detection and prognostic assessment of PDAC, the sensitivity and specificity of circulating CA19-9 detection is still poor [4, 5]. At present, treatment options for patients with PDAC are limited. Gemcitabine-based chemotherapy remains the standard of care for patients with advanced PDAC, but intrinsic and acquired chemoresistance is common . The epithelial growth factor receptor inhibitor erlotinib is the only targeted agent currently used in the treatment of PDCA, but only a fraction of PDAC patients can benefit from it . Therefore, to develop more efficient diagnostic and therapeutic strategies for PDAC, we need to elucidate the molecular mechanisms underlying its development and progression.
MicroRNAs (miRNAs) are small non-coding RNAs that inhibit the expression of target genes by base pairing to complementary sites in the 3′-untranslated region of target mRNAs, leading to translational repression or the degradation of the target mRNAs . Recent studies have shown that miRNAs elicit oncogenic or tumor-suppressive functions by directly targeting oncogenes or tumor suppressor genes, respectively [8–10]. Deregulated miRNAs have been found to play pivotal roles in PDAC development and progression by affecting multiple cellular processes, such as cell proliferation, apoptosis, survival, invasion, metastasis, and chemotherapeutic resistance of PDAC .
miR-506, located on Xq27.3, was identified as a member of the miR-506-514 cluster (including miR-506, miR-507, miR-508, miR-509, miR-510, miR-513 and miR-514) and was preferentially expressed in the testes of primates . miR-506 was shown to inhibit tumor progression by suppressing epithelial-to-mesenchymal transition (EMT), cell migration and invasion, cell proliferation, and angiogenesis and by promoting cell senescence in ovarian, gastric, breast, colorectal, and liver cancers as well as glioma [13–26]. In contrast, the miR-506-514 cluster was shown to be an activator in initiating tumor transformation in malignant melanoma . In pancreatic cancer cells, miR-506 was shown to inhibit cell proliferation by targeting Pim-3 proto-oncogene (PIM3), a member of the proto-oncogene PIM family . Using real-time reverse transcription-polymerase chain reaction (qRT-PCR), Du et al.  examined the expression of miR-506 in 38 pancreatic cancers and matched adjacent normal tissues and found that 71% (27/38) of cases exhibited down-regulated miR-506 expression.
In this study, using miRNA in situ hybridization (ISH), we examined the expression of miR-506 in 113 PDAC and 87 matched normal pancreatic tissues. Considering the complicated constituents of pancreatic tissue, we believed that miRNA ISH that can be linked to morphology is a more accurate option to demonstrate miR-506 expression in specific cells. We evaluated the expression of miR-506 in PDAC cells, normal pancreatic ductal cells, acinar cells, and islands. In addition, we analyzed the relationship between miR-506 expression and clinicopathologic parameters to elucidate the role of miR-506 in the progression of PDAC.
Patients and tissue samples
We collected 200 formalin-fixed, paraffin-embedded pancreatic tissue samples (including 113 cases of tumor tissue and 87 cases of non-tumor tissue in the resection margin) from the Department of Pathology at Tianjin Medical University Cancer Institute and Hospital (Tianjin, China). All samples were from 113 patients with PDAC who underwent surgical operation between 2007 and 2010, and none of the patients received any preoperative chemotherapy or radiotherapy. All specimens and clinical data were collected after our study received approval from Institutional Review Board of Tianjin Medical University Cancer Institute and Hospital.
Tissue microarray construction
Tissue microarrays (TMAs) were constructed using a manual tissue microarray instrument (Beecher Instruments, Sun Prairie, WI, USA) equipped with a 2.0-mm punch needle, as described previously . Five TMA blocks were prepared for the 200 pancreatic tissue specimens. For each tissue sample, the typical area was selected based on the appearance of the original hematoxylin and eosin-stained slides. For the non-tumor tissue in surgical resection, we chose the typical areas with normal pancreatic ducts. For the 87 patients with both PDAC and non-tumor tissues, the matched tumor and non-tumor tissues were placed in adjacent cores.
The 4-μm paraffin-embedded TMA sections were hybridized with the double-DIG-labelled miRCURY LNATM detection probe, hsa-miR-506 (38314-15, Exiqon, Woburn, MA, USA) for 2 h at 55°C, as described previously [13, 14]. The digoxigenins were detected with a polyclonal anti-DIG antibody and an alkaline phosphatase-conjugated second antibody (Ventana, Tucson, AZ, USA), using Nitroblue tetrazolium-5-bromo-4-chloro-3-indolyl phosphate (NBT-BCIP) as the substrate. The LNA U6 snRNA probe (Exiqon, Woburn, MA, USA) was used as a positive control for every TMA core, with blue staining in the nucleus. For miR-506, blue staining in the cytoplasm was defined as positive signals. Signals in tumor cells and pancreatic non-tumor tissue (pancreatic ducts, acinar cells, and islands) were quantified by two senior pathologists, using a previously described scoring system [13, 14] with some modifications. The signal intensity (0, no signal; 1, weak signal; 2, intermediate signal; and 3, strong signal) and the percentage of positive cells (0, 0%; 1, <25%; 2, 25%–50%; and 3, >50%) were multiplied to obtain a score (0, 1, 2, 3, 4, 6, or 9). Low and high miR-506 expression levels were defined as scores of <4 and ≥4, respectively.
Statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA) and SPSS version 17.0 softwares (SPSS Inc., Chicago, IL, USA). Student’s t test and the Chi square test were used to compare miR-506 levels between different groups. All statistical tests were two-sided, and P values less than 0.05 were considered statistically significant.
Of the 113 patients with PDAC, 64 (56.6%) were men, and 49 (43.4%) were women. Patient age ranged from 31 to 79 (median, 59) years. Fifty-two (46.0%) tumors were found in the head, 33 (29.2%) in the uncinate process, and 28 (24.8%) in the body and tail of the pancreas. Of the 113 PDAC patients, 79 (69.9%) underwent pancreaticoduodenectomy, 30 (26.5%) distal pancreatectomy plus splenectomy, 2 (1.8%) pancreaticoduodenectomy plus portal vein replacement, 1 (0.9%) total pancreas resection, and 1 (0.9%) pylorus-preserving pancreaticoduodenectomy. The largest tumor diameter ranged from 1 to 10 cm (4.2 ± 1.8 cm). Histopathologically, 10 (8.9%), 59 (52.2%) and 44 (38.9%) PDACs were well, moderately, and poorly differentiated, respectively. Twenty-eight (24.8%) PDACs were limited to the pancreas (pathologic T category (pT1 and pT2), whereas 85 (75.2%) PDACs invaded adjacent organs or spread to the abdominal cavity (pT3 and pT4). Except the 15 patients for whom not enough information was available to evaluate the status of lymph node metastasis, lymph node metastasis was found in 21 (18.6%) patients, and 77 (68.1%) patients had no lymph node metastasis.
miR-506 expression was up-regulated in PDAC compared with normal pancreatic ducts
PDAC showed a higher miR-506 expression compared with pancreatic intraepithelial neoplasia
Associations between miR-506 expression and clinicopathologic parameters
The relationship between miR-506 expression and clinicopathologic parameters in 110 PDACs
No. of patients
miR-506 expression [case (%)]
Body and tail
Tumor size (cm)
Lymph node metastasisa
In this study, we demonstrated that miR-506 was up-regulated in PDACs compared with normal pancreatic ducts. Du et al.  examined miR-506 expression in 38 PDAC patients with RT-PCR and showed that miR-506 was significantly down-regulated in PDACs compared with normal adjacent tissues. The reasons for the inconsistency may be owing to differences in the sample size and the testing method. One of the advantages of miRNA ISH is the combination of the morphology and the expression of miRNAs. The structure of the pancreas is complex and includes pancreatic ducts, acinus, and islands. Moreover, in normal pancreatic lobules, there are many more acinar cells than ductal cells. We think that, because most PDACs originate from ductal cells , comparing the expression of miR-506 in PDAC cells with that in normal pancreatic ductal cells to evaluate the role of miR-506 in PDAC is more accurate. Furthermore, one typical feature of PDAC is the obvious desmoplastic response. In addition, PDACs often have obscure boundaries, and the tumor cells usually invade into adjacent pancreatic acinus cells and pancreatic islands. Therefore, it is important to distinguish tumor cells from stromal cells and differentiate pancreatic ductal cells from the surrounding acinus and islands. The results of qRT-PCR are for the whole cells that were used for RNA extraction. If we want to evaluate the expression of specific cells, laser capture microdissection is suggested before RNA extraction and qRT-PCR. However, miRNA ISH has its disadvantages, such as it not being a quantitative method. To mitigate the disadvantage, we used a semi-quantitative scoring system, as described in the Methods section, and performed the analysis in a relatively large patient population. Further studies are warranted to identify the expression of miR-506 in PDAC.
Increasing evidence has demonstrated that PanIN is the most direct precursor lesion of PDAC . Studies have shown that patients with benign pancreatic tumors whose surgery margin had high-grade PanIN were diagnosed with PDAC several months or several years after the surgery [35–37]. The molecular alteration is accumulated during the progression from PanIN to PDAC . Kirsten ras oncogene (KRAS) mutation was found in 36% of PanIN1A cases, 44% of PanIN1B cases, 87% of PanIN2/3 cases, and more than 90% of PDACs [35, 39]; therefore, KRAS mutation was considered an early genetic alteration event of PDAC . Cyclin-dependent kinase inhibitor 2A (CDKN2A) mutation can be found in PanIN2, and mutations of tumor protein p53 (TP53), breast cancer 2 (BRCA2), and SMAD family member 4 (SMAD4) were found mainly in PanIN3 or PDAC, which were recognized as late events of PDAC initiation [41, 42]. In our study, because of the limitation of TMA, we found only three low-grade PanINs in the non-tumor tissue or among tumor cells. However, in all three cases, miR-506 expression was higher in PDAC than in PanIN. Considering that miR-506 was up-regulated in PDAC compared with normal pancreatic ducts and low-grade PanIN, miR-506 may play a role as an oncogene in the late phase of PDAC initiation. Alternatively, the activation of miR-506 expression may be a result of feedback response of the tumor suppression system to oncogenic signaling. For house-keeping tumor suppressor genes such as TP53, such an oncogene-activated elevation is an important mechanism [43, 44]. Future studies will be needed to differentiate these two scenarios.
miR-506 was shown to inhibit EMT by targeting snail family transcriptional repressor 2 (SNAI2), vimentin (VIM), cadherin 2 (CDH2), CD151 molecule (CD151), ETS proto-oncogene 1 (ETS1), and enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) in ovarian, breast, gastric, and colorectal cancers [13, 14, 17, 45, 46]. In our study, miR-506 expression was significantly higher in well and moderately differentiated PDACs than in poorly differentiated ones. Compared with well and moderately differentiated tumors, the tumor glands in poorly differentiated PDACs are more irregular; they are even replaced with solid nests or trabeculae. Consequently, the expression of E-cadherin and cell adhesion in cancer cells is lower in poorly differentiated PDACs than in well and moderately differentiated ones [47, 48], which was consistent with our finding of miR-506 down-regulation in poorly differentiated PDACs. Further studies will be needed to evaluate cause and effect between miR-506 expression and tumor differentiation.
Invasion and metastasis were involved in tumor progression. According to the TNM staging system of PDAC , the cancer cells at pT3 and pT4 stages (beyond the pancreas) are more invasive than those at pT1 and pT2 stages (limited to the pancreas). Our data showed that miR-506 expression was lower in cancer cells at pT3 and pT4 stages than in those at pT1 and pT2 stages. Furthermore, we found lower levels of miR-506 in the PDACs with lymph node metastasis than in those without metastasis. Therefore, miR-506 is likely to function as a tumor suppressor to attenuate progression of PDAC.
In summary, by using miRNA ISH in a large-scale study of PDAC and normal pancreatic tissues, we demonstrated that miR-506 was up-regulated in PDAC compared with normal pancreatic ducts. On the other hand, miR-506 expression was negatively associated with pT stage and lymph node metastasis, suggesting that miR-506 might inhibit the de-differentiation and invasion of PDAC cells as a tumor suppressor. The bimodal pattern of miR-506 expression in different phases of PDAC suggests that miR-506 either plays a role as an oncogene in the tumorigenesis and a tumor suppressor in the progression or serves as a house-keeping, tumor-suppressing miRNA, whose expression can be activated by oncogenic signals in early development to hinder the progression of PDAC. Further studies are needed to gain deeper insights into the role and mechanism of miR-506 in PDAC.
YS, JW and BCS conceived of the study and participated in its design and coordination. RF and ZQQ performed TMA construction. JYZ and YRZ performed miRNA ISH. YS, RFC, JYZ and LS performed the statistical analyses and interpretation. YS and RFC drafted the manuscript. All authors read and approved the final manuscript.
This study was partially supported by the National Natural Science Foundation of China (Nos. 81472263 and 81201651), a Grant from the Tianjin Municipal Science and Technology Commission (No. 14JCYBJC27500), and the National Key Clinical Specialist Construction Programs of China (No. 2013-544). J. Wang was supported by the National Natural Science Foundation of China (No. 81472264) and a Grant from the Tianjin Municipal Science and Technology Commission (No. 13JCYBJC37400).
The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.View ArticlePubMedGoogle Scholar
- He Y, Zheng R, Li D, Zeng H, Zhang S, Chen W. Pancreatic cancer incidence and mortality patterns in China, 2011. Chin J Cancer Res. 2015;27(1):29–37.PubMedPubMed CentralGoogle Scholar
- Rosty C, Goggins M. Early detection of pancreatic carcinoma. Hematol Oncol Clin N Am. 2002;16(1):37–52.View ArticleGoogle Scholar
- Distler M, Pilarsky E, Kersting S, Grutzmann R. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas—a retrospective tumor marker prognostic study. Int J Surg. 2013;11(10):1067–72.View ArticlePubMedGoogle Scholar
- Park JK, Paik WH, Ryu JK, Kim YT, Kim YJ, Kim J, et al. Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1446 patients from the pancreatic cancer cohort in a single institution. PLoS One. 2013;8(11):e78977.View ArticlePubMedPubMed CentralGoogle Scholar
- Van den Broeck A, Gremeaux L, Topal B, Vankelecom H. Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine. BMC Cancer. 2012;12:354.View ArticlePubMedGoogle Scholar
- Kadera BE, Toste PA, Wu N, Li L, Nguyen AH, Dawson DW, et al. Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition. Clin Cancer Res. 2015;21(1):157–65.View ArticlePubMedGoogle Scholar
- Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10(10):704–14.View ArticlePubMedPubMed CentralGoogle Scholar
- Sun Y, Guo F, Bagnoli M, Xue FX, Sun BC, Shmulevich I, et al. Key nodes of a microRNA network associated with the integrated mesenchymal subtype of high-grade serous ovarian cancer. Chin J Cancer. 2015;34(1):28–40.View ArticlePubMedPubMed CentralGoogle Scholar
- Faggad A, Kasajima A, Weichert W, Stenzinger A, Elwali NE, Dietel M, et al. Down-regulation of the microRNA processing enzyme Dicer is a prognostic factor in human colorectal cancer. Histopathology. 2012;61(4):552–61.PubMedGoogle Scholar
- Sun L, Chua CY, Tian W, Zhang Z, Chiao PJ, Zhang W. MicroRNA signaling pathway network in pancreatic ductal adenocarcinoma. J Genet Genomics. 2015;42(10):563–77.View ArticlePubMedGoogle Scholar
- Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet. 2005;37(7):766–70.View ArticlePubMedGoogle Scholar
- Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 2013;23(2):186–99.View ArticlePubMedPubMed CentralGoogle Scholar
- Sun Y, Hu L, Zheng H, Bagnoli M, Guo Y, Rupaimoole R, et al. MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol. 2015;235(1):25–36.View ArticlePubMedGoogle Scholar
- Liu G, Sun Y, Ji P, Li X, Cogdell D, Yang D, et al. MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer. J Pathol. 2014;233(3):308–18.View ArticlePubMedPubMed CentralGoogle Scholar
- Deng J, Lei W, Xiang X, Zhang L, Yu F, Chen J, et al. MicroRNA-506 inhibits gastric cancer proliferation and invasion by directly targeting Yap1. Tumour Biol. 2015;36(9):6823–31.View ArticlePubMedGoogle Scholar
- Li Z, Liu Z, Dong S, Zhang J, Tan J, Wang Y, et al. miR-506 inhibits epithelial-to-mesenchymal transition and angiogenesis in gastric cancer. Am J Pathol. 2015;185(9):2412–20.View ArticlePubMedGoogle Scholar
- Sakimura S, Sugimachi K, Kurashige J, Ueda M, Hirata H, Nambara S, et al. The miR-506-induced epithelial-mesenchymal transition is involved in poor prognosis for patients with gastric cancer. Ann Surg Oncol. 2015;22(Suppl 3):1436–43.View ArticleGoogle Scholar
- Yu F, Lv M, Li D, Cai H, Ma L, Luo Q, et al. MiR-506 over-expression inhibits proliferation and metastasis of breast cancer cells. Med Sci Monit. 2015;21:1687–92.View ArticlePubMedPubMed CentralGoogle Scholar
- Sun G, Liu Y, Wang K, Xu Z. miR-506 regulates breast cancer cell metastasis by targeting IQGAP1. Int J Oncol. 2015;47(5):1963–70.PubMedGoogle Scholar
- Zhang Y, Lin C, Liao G, Liu S, Ding J, Tang F, et al. MicroRNA-506 suppresses tumor proliferation and metastasis in colon cancer by directly targeting the oncogene EZH2. Oncotarget. 2015;6(32):32586–601.PubMedPubMed CentralGoogle Scholar
- Chen Z, Liu S, Tian L, Wu M, Ai F, Tang W, et al. miR-124 and miR-506 inhibit colorectal cancer progression by targeting DNMT3B and DNMT1. Oncotarget. 2015;6(35):38139–50.PubMedPubMed CentralGoogle Scholar
- Wang Y, Cui M, Sun BD, Liu FB, Zhang XD, Ye LH. MiR-506 suppresses proliferation of hepatoma cells through targeting YAP mRNA 3′UTR. Acta Pharmacol Sin. 2014;35(9):1207–14.View ArticlePubMedPubMed CentralGoogle Scholar
- Deng Q, Xie L, Li H. MiR-506 suppresses cell proliferation and tumor growth by targeting Rho-associated protein kinase 1 in hepatocellular carcinoma. Biochem Biophys Res Commun. 2015;467(4):921–7.View ArticlePubMedGoogle Scholar
- Peng T, Zhou L, Zuo L, Luan Y. miR-506 functions as a tumor suppressor in glioma by targeting STAT3. Oncol Rep. 2016;35(2):1057–64.PubMedGoogle Scholar
- Liu G, Xue F, Zhang W. miR-506: a regulator of chemo-sensitivity through suppression of the RAD51-homologous recombination axis. Chin J Cancer. 2015;34(11):485–7.PubMedGoogle Scholar
- Streicher KL, Zhu W, Lehmann KP, Georgantas RW, Morehouse CA, Brohawn P, et al. A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth. Oncogene. 2012;31(12):1558–70.View ArticlePubMedGoogle Scholar
- Du J, Zheng X, Cai S, Zhu Z, Tan J, Hu B, et al. MicroRNA506 participates in pancreatic cancer pathogenesis by targeting PIM3. Mol Med Rep. 2015;12(4):5121–6.PubMedGoogle Scholar
- Sun Y, Yokoi K, Li H, Gao J, Hu L, Liu B, et al. NGAL expression is elevated in both colorectal adenoma-carcinoma sequence and cancer progression and enhances tumorigenesis in xenograft mouse models. Clin Cancer Res. 2011;17(13):4331–40.View ArticlePubMedPubMed CentralGoogle Scholar
- Koorstra JB, Feldmann G, Habbe N, Maitra A. Morphogenesis of pancreatic cancer: role of pancreatic intraepithelial neoplasia (PanINs). Langenbecks Arch Surg. 2008;393(4):561–70.View ArticlePubMedPubMed CentralGoogle Scholar
- Ledniczky G, Bognar G, Bereczky B, Barabas L, Ondrejka P. Precursors of pancreatic cancer: intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasms (IPMN). Magy Seb. 2009;62(1):22–6.View ArticlePubMedGoogle Scholar
- Hwang IK, Kim H, Lee YS, Kim J, Cho JY, Yoon YS, et al. Presence of pancreatic intraepithelial neoplasia-3 in a background of chronic pancreatitis in pancreatic cancer patients. Cancer Sci. 2015;106(10):1408–13.View ArticlePubMedPubMed CentralGoogle Scholar
- Andea A, Sarkar F, Adsay VN. Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod Pathol. 2003;16(10):996–1006.View ArticlePubMedGoogle Scholar
- Zamboni G, Hirabayashi K, Castelli P, Lennon AM. Precancerous lesions of the pancreas. Best Pract Res Clin Gastroenterol. 2013;27(2):299–322.View ArticlePubMedGoogle Scholar
- Fernandez C, Chetaille B, Tasei AM, Sastre B, Sahel J, Payan-Defais MJ. From pancreatic intraepithelial neoplasia to cancer: a dramatic progression with K-ras status analysis. Gastroenterol Clin Biol. 2005;29(4):465–8.View ArticlePubMedGoogle Scholar
- Takaori K, Hruban RH, Maitra A, Tanigawa N. Pancreatic intraepithelial neoplasia. Pancreas. 2004;28(3):257–62.View ArticlePubMedGoogle Scholar
- Oda Y, Aishima S, Morimatsu K, Shindo K, Fujino M, Mizuuchi Y, et al. Pancreatic intraepithelial neoplasia in the background of invasive ductal carcinoma of the pancreas as a prognostic factor. Histopathology. 2014;65(3):389–97.View ArticlePubMedGoogle Scholar
- Yachida S, Iacobuzio-Donahue CA. The pathology and genetics of metastatic pancreatic cancer. Arch Pathol Lab Med. 2009;133(3):413–22.PubMedGoogle Scholar
- Lohr M, Kloppel G, Maisonneuve P, Lowenfels AB, Luttges J. Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia. 2005;7(1):17–23.View ArticlePubMedPubMed CentralGoogle Scholar
- Sinn BV, Striefler JK, Rudl MA, Lehmann A, Bahra M, Denkert C, et al. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma. Pancreas. 2014;43(4):578–83.View ArticlePubMedGoogle Scholar
- Goggins M, Hruban RH, Kern SE. BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J Pathol. 2000;156(5):1767–71.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang Q, Liu H, Liu T, Shu S, Jiang H, Cheng S, et al. BRCA2 dysfunction promotes malignant transformation of pancreatic intraepithelial neoplasia. Anticancer Agents Med Chem. 2013;13(2):261–9.View ArticlePubMedGoogle Scholar
- Suh SS, Yoo JY, Nuovo GJ, Jeon YJ, Kim S, Lee TJ, et al. MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme. Proc Natl Acad Sci USA. 2012;109(14):5316–21.View ArticlePubMedPubMed CentralGoogle Scholar
- Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S, et al. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA. 2011;305(1):59–67.View ArticlePubMedPubMed CentralGoogle Scholar
- Wu J, Peng X, Zhou A, Qiao M, Wu H, Xiao H, et al. MiR-506 inhibits PRRSV replication in MARC-145 cells via CD151. Mol Cell Biochem. 2014;394(1–2):275–81.View ArticlePubMedGoogle Scholar
- Zhang XB, Song L, Wen HJ, Bai XX, Li ZJ, Ma LJ. Upregulation of microRNA-31 targeting integrin alpha5 suppresses tumor cell invasion and metastasis by indirectly regulating PI3K/AKT pathway in human gastric cancer SGC7901 cells. Tumour Biol. 2016;37(6):8317–25.View ArticlePubMedGoogle Scholar
- Shimamura T, Sakamoto M, Ino Y, Sato Y, Shimada K, Kosuge T, et al. Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: relationship to e-cadherin expression. J Clin Oncol. 2003;21(4):659–67.View ArticlePubMedGoogle Scholar
- Joo YE, Rew JS, Park CS, Kim SJ. Expression of E-cadherin, alpha- and beta-catenins in patients with pancreatic adenocarcinoma. Pancreatology. 2002;2(2):129–37.View ArticlePubMedGoogle Scholar
- Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4.View ArticlePubMedGoogle Scholar